The aim of this study was to compare conservative versus aggressive strategy in patients with intermediate lesions with angiography guidance alone.

To investigate whether conservative revascularization using criteria of 70% diameter stenosis would be non-inferior to aggressive revascularization using criteria of 50% diameter stenosis in coronary intermediate lesions, we conducted the Conservative Revascularization versus Aggressive Revascularization for Coronary Stenting with Everolimus-Eluting Stents (SMART-CASE) trial.

Inclusion Criteria:

• Intermediate coronary lesion(s) (diameter stenosis between 50% and 70% by quantitative coronary analysis)
• Target lesion(s) must be located in a native coronary artery with diameter of ≥2.25 mm and ≤4.25 mm

Exclusion Criteria:

• cardiogenic shock
• myocardial infarction (MI) within 48 hours
• left main lesion
• drug-eluting stent implantation in the target vessel prior to enrollment
• ≥2 chronic total occlusions in major coronary territories
• history of bleeding diathesis or known coagulopathy
• gastrointestinal or genitourinary bleeding within 3 months or major surgery within 2 months
• platelet count <100,000 cells/mm3
• planned elective surgical procedure that would necessitate interruption of thienopyridine during the first 6 months after enrollment
• non-cardiac co-morbid conditions with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).